Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.
Tropé C, Hogberg T, Kaern J, Bertelsen K, Bjorkholm E, Boman K, Himmelmann A, Horvath G, Jacobsen A, Kuoppola T, Vartianen J, Lund B, Onsrud M, Puistola U, Salmi T, Scheistroen M, Sandvei R, Simonsen E, Sorbe B, Tholander B, Westberg R. Tropé C, et al. Among authors: boman k. Ann Oncol. 1998 Dec;9(12):1301-7. doi: 10.1023/a:1008400324892. Ann Oncol. 1998. PMID: 9932160 Free article. Clinical Trial.
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C; Yondelis Ovarian Cancer Group. Del Campo JM, et al. Among authors: boman k. Ann Oncol. 2009 Nov;20(11):1794-802. doi: 10.1093/annonc/mdp198. Epub 2009 Jun 25. Ann Oncol. 2009. PMID: 19556318 Free article. Clinical Trial.
A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
Sorbe B, Graflund M, Nygren L, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M, Malmström H. Sorbe B, et al. Among authors: boman k. Int J Oncol. 2012 Mar;40(3):773-81. doi: 10.3892/ijo.2011.1286. Epub 2011 Dec 7. Int J Oncol. 2012. PMID: 22159569 Clinical Trial.
[A new, more expensive agent against ovarian cancer. Worth its price?].
Högberg T, Karlsson G, Ridderheim M, Boman K, Frankendal B, Horvath G, Sorbe B, Strang P, Rosenberg P. Högberg T, et al. Among authors: boman k. Lakartidningen. 1997 Jan 8;94(1-2):21-4. Lakartidningen. 1997. PMID: 9053597 Swedish. No abstract available.
411 results